vedolizumab
takeda
[' vedo', 'vedo']
reprevio trial shows substantially lower risk of cd endoscopic recurrence after resection with vedo vs pbo #ecco2023 #ecco23 
Deputy ed @lancetgastrohep - liver lover but fond of all things gastro. Former NatRevGastro. Commonly on 2 wheels. All nonsense entirely mine.